$DARE
Dare Bioscience, Inc.

2015 Q1 Form 10-Q Financial Statement

#000156459016017298 Filed on May 02, 2016

View on sec.gov

Income Statement

Concept 2015 Q1
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.680M
YoY Change 77.48%
% of Gross Profit
Research & Development $5.021M
YoY Change 235.85%
% of Gross Profit
Depreciation & Amortization $41.00K
YoY Change 13.89%
% of Gross Profit
Operating Expenses $7.702M
YoY Change 156.31%
Operating Profit
YoY Change
Interest Expense $721.0K
YoY Change 56.4%
% of Operating Profit
Other Income/Expense, Net -$718.0K
YoY Change -1731.82%
Pretax Income -$8.430M
YoY Change 189.69%
Income Tax
% Of Pretax Income
Net Earnings -$8.420M
YoY Change 188.95%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$4.132M
COMMON SHARES
Basic Shares Outstanding 20.38M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.32M
YoY Change 564.94%
Cash & Equivalents $56.32M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $2.270M
Other Receivables $0.00
Total Short-Term Assets $58.58M
YoY Change 409.36%
LONG-TERM ASSETS
Property, Plant & Equipment $330.0K
YoY Change 47.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $469.0K
YoY Change 260.77%
Total Long-Term Assets $799.0K
YoY Change 126.35%
TOTAL ASSETS
Total Short-Term Assets $58.58M
Total Long-Term Assets $799.0K
Total Assets $59.38M
YoY Change 400.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.682M
YoY Change -22.13%
Accrued Expenses $2.736M
YoY Change 83.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change -100.0%
Long-Term Debt Due $840.0K
YoY Change -73.75%
Total Short-Term Liabilities $5.289M
YoY Change -78.13%
LONG-TERM LIABILITIES
Long-Term Debt $13.58M
YoY Change 490.43%
Other Long-Term Liabilities $110.0K
YoY Change 685.71%
Total Long-Term Liabilities $13.68M
YoY Change 329.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.289M
Total Long-Term Liabilities $13.68M
Total Liabilities $18.97M
YoY Change -30.67%
SHAREHOLDERS EQUITY
Retained Earnings -$130.2M
YoY Change
Common Stock $170.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.41M
YoY Change
Total Liabilities & Shareholders Equity $59.38M
YoY Change 400.94%

Cashflow Statement

Concept 2015 Q1
OPERATING ACTIVITIES
Net Income -$8.420M
YoY Change 188.95%
Depreciation, Depletion And Amortization $41.00K
YoY Change 13.89%
Cash From Operating Activities -$7.940M
YoY Change 116.35%
INVESTING ACTIVITIES
Capital Expenditures $29.00K
YoY Change 107.14%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$30.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.411M
YoY Change 8829.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.11M
YoY Change 97.14%
NET CHANGE
Cash From Operating Activities -7.940M
Cash From Investing Activities -30.00K
Cash From Financing Activities 13.11M
Net Change In Cash 5.140M
YoY Change 72.48%
FREE CASH FLOW
Cash From Operating Activities -$7.940M
Capital Expenditures $29.00K
Free Cash Flow -$7.969M
YoY Change 116.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2015Q1 us-gaap Interest Expense
InterestExpense
721000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
7702000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
12888000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3118000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2681000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-8428000
CY2016Q1 us-gaap Other Expenses
OtherExpenses
7000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
41000
CY2016Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
127000
CY2015Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
515000
CY2016Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000
CY2016Q1 ceru Increase Decrease In Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
192000
CY2015Q1 ceru Increase Decrease In Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
120000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
141000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
378000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-724000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-761000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13260000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7941000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
359000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
16000
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2016Q1 us-gaap Interest Expense
InterestExpense
663000
CY2015Q1 us-gaap Other Expenses
OtherExpenses
8000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-654000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-726000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-13542000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27362643
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20350557
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
741000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
440000
CY2016Q1 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
124000
CY2015Q1 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
-6000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
61000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
CY2016Q1 us-gaap Decrease In Restricted Cash
DecreaseInRestrictedCash
117000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-242000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-29000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2411000
CY2015Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
15000000
CY2016Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1932000
CY2015Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3921000
CY2015Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
359000
CY2015Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
19000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1891000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13112000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15393000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5142000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51174000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56316000
CY2016Q1 us-gaap Interest Paid Net
InterestPaidNet
372000
CY2015Q1 us-gaap Interest Paid Net
InterestPaidNet
163000
CY2016Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NATURE OF BUSINESS AND OPERATIONS</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nature of Business&#160;&#8212; Cerulean Pharma&#160;Inc. (the &#8220;Company&#8221;) was incorporated on November&#160;28, 2005, as a Delaware corporation and is located in Waltham, Massachusetts. The Company was formed to develop novel, nanotechnology-based therapeutics in the areas of oncology and other diseases. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation &#8212; The condensed consolidated financial statements include the accounts of the Company and its subsidiary, Cerulean Pharma Australia Pty&#160;Ltd, a wholly owned Australian-based proprietary limited company. All intercompany accounts and transactions have been eliminated. The consolidated interim financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of and for the year ended December&#160;31, 2015, and notes thereto, included in the Company&#8217;s Annual Report on Form 10-K, which was filed with the SEC on March 10, 2016 (the &#8220;2015 10-K&#8221;).</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company&#8217;s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company&#8217;s financial position as of March 31, 2016 and the results of its operations and cash flows for the three months ended March 31, 2016 and 2015. Such adjustments are of a normal and recurring nature. The results for the three months ended March 31, 2016, are not indicative of the results for the year ending December 31, 2016, or for any future period.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has an accumulated deficit of $174.9 million at March 31, 2016. The Company has financed its operations primarily through private placements of its preferred stock, proceeds from borrowings, an initial public offering completed in 2014 and a follow-on offering completed in 2015. The Company has not completed development of any product candidate and has devoted substantially all of its financial resources and efforts to research and development, including preclinical and clinical development. Accordingly, the Company will continue to depend on its ability to raise capital through equity and debt issuances and/or through strategic partnerships. The Company expects to continue to incur significant expenses and increasing operating losses for at least several years.&nbsp;&nbsp;The Company believes that its cash and cash equivalents as of March 31, 2016, will be able to fund operating expenses, debt service and capital expenditure requirements for at least twelve months from the filing date of this Quarterly Report on Form 10-Q.&nbsp;&nbsp;</p></div>
CY2015Q4 ceru Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2631000
CY2016Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-28
CY2016Q1 ceru Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2579000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.61
CY2016Q1 ceru Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
1404000
CY2015Q4 ceru Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
945000
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
749000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1864000
CY2016Q1 us-gaap Interest Payable Current
InterestPayableCurrent
116000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
136000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
711000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
883000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3454926
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
547070
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
10410
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3991586
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2695996
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1159945
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.39
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.98
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.88
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.06
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.79
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.72
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y3M18D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
18000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0131
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0145
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0189
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0169
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.61
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.63

Files In Submission

Name View Source Status
0001564590-16-017298-index-headers.html Edgar Link pending
0001564590-16-017298-index.html Edgar Link pending
0001564590-16-017298.txt Edgar Link pending
0001564590-16-017298-xbrl.zip Edgar Link pending
ceru-10q_20160331.htm Edgar Link pending
ceru-20160331.xml Edgar Link completed
ceru-20160331.xsd Edgar Link pending
ceru-20160331_cal.xml Edgar Link unprocessable
ceru-20160331_def.xml Edgar Link unprocessable
ceru-20160331_lab.xml Edgar Link unprocessable
ceru-20160331_pre.xml Edgar Link unprocessable
ceru-ex311_11.htm Edgar Link pending
ceru-ex312_10.htm Edgar Link pending
ceru-ex321_7.htm Edgar Link pending
ceru-ex322_12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending